SNN

Smith & Nephew plc

$33.34

+$0.46 (+1.40%)

Jan 5, 2026

Price History (1Y)

Analysis

Smith & Nephew plc is a leading global medical technology business in the sector of Healthcare and industry of Medical Devices. The company has a significant scale with a market capitalization of $14.38 billion, annual revenue of $5.94 billion, and approximately 17,000 employees. The company's financial health indicates a moderate level of profitability, with gross margin at 70.6%, operating margin at 14.5%, and profit margin at 8.3%. Returns on equity (9.1%) and assets (5.8%) are also within reasonable ranges. The balance sheet shows a substantial amount of debt ($3.45 billion) against cash reserves ($676 million), resulting in a debt-to-equity ratio of 62.39. However, the current ratio is satisfactory at 3.00. In terms of valuation context, Smith & Nephew plc has a price-to-earnings (P/E) ratio of 29.50 and forward P/E ratio of 18.48. Revenue growth has been steady at 4.7% year-over-year, while earnings growth has been significantly higher at 35.9%. The company offers an unusually high dividend yield of 232.0%, although the payout ratio is relatively high at 67.2%.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Visit website →

Key Statistics

Market Cap: $14.38B
P/E Ratio: 29.50
52-Week High: $38.79
52-Week Low: $23.69
Avg Volume: 582.22K
Beta: 0.64
Dividend Yield: 232.00%

Company Info

Industry: Medical Devices
Exchange: NYQ
Country: United Kingdom
Employees: 17,000